Cassava Sciences | PTIE - Assets


Cassava Sciences reported $129.73M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Abbott USD 86.71B 2.53B Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Cassava Sciences USD 129.73M 5.65M Sep/2025
Eisai JPY 1.49T 48.22B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Geron USD 567.38M 12.18M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novavax USD 1.18B 156.66M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025